ADC Therapeutics SA (NYSE: ADCT) has announced updated data from the LOTIS-7 Phase 1b open-label clinical trial, which evaluates the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The data will be presented at the European Hematology Association 2025 Congress (EHA2025) in Milan, Italy. The trial results indicate a clinically meaningful benefit, with an overall response rate of 93.3% and a complete response rate of 86.7% among 30 evaluable patients. The combination treatment is generally well-tolerated, with a manageable safety profile, and the company is expanding the study enrollment to 100 patients at a 150 µg/kg dose. The data will also be shared at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland. ADC Therapeutics will host a conference call to discuss these results.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。